Everest Medicines Unveils Breakthroughs in AI+mRNA Platform, Reinforces Global Leadership in Next-Gen mRNA Innovation

Everest Medicines is solidifying its position as a global leader in next-generation mRNA innovation, announcing significant advancements in its proprietary AI+mRNA platform. These breakthroughs, highlighted at the company’s “2025 Everest Medicines mRNA Platform R&D Day” in Shanghai, underscore a strategic shift towards driving internal innovation and a “dual-engine” growth model.

At the core of Everest’s success is its fully integrated and localized AI+mRNA platform. This sophisticated system encompasses everything from AI-powered antigen design and mRNA sequence optimization to proprietary Lipid Nanoparticle (LNP) delivery technologies and scalable Good Manufacturing Practice (GMP)-compliant manufacturing. The platform’s efficacy has already been clinically validated, notably through Everest’s mRNA COVID-19 vaccine candidate, PTX-COVID19-B, which demonstrated non-inferiority to Pfizer/BioNTech’s Comirnaty® in a global Phase II trial.

A key highlight of the R&D Day was the unveiling of progress on three innovative assets developed using this platform. EVM16, a personalized mRNA cancer vaccine, leverages Everest’s third-generation AI-based neoantigen prediction algorithm, EVER-NEO-1. This algorithm precisely identifies patient-specific tumor mutations, enabling the creation of customized mRNA sequences delivered via LNPs to stimulate targeted T-cell responses. Early results from an investigator-initiated trial for EVM16 have shown robust, mutation-specific T-cell responses, validating the AI algorithm’s reliability.

Another promising candidate, EVM14, is an off-the-shelf therapeutic mRNA vaccine targeting five tumor-associated antigens relevant to various squamous carcinomas. Preclinical data suggest EVM14’s potential to enhance immune memory and reduce tumor recurrence. The program has already received FDA Investigational New Drug (IND) clearance, with the first clinical batch successfully released from Everest’s Jiashan manufacturing facility and expected to reach U.S. clinical centers by mid-August.

Furthermore, Everest Medicines is making significant strides in its in vivo CAR-T program, which utilizes a proprietary targeted LNP (tLNP) delivery system. This innovative approach allows for the in vivo generation of CAR-T cells, eliminating the need for lymphodepletion and offering advantages like off-the-shelf availability and controllable dosing. Preclinical studies in humanized mouse and non-human primate models have shown high T-cell transfection rates and effective B-cell clearance, positioning this therapy as a potential game-changer in oncology and autoimmune diseases.

Rogers Yongqing Luo, CEO of Everest Medicines, emphasized that these advancements not only accelerate the company’s “dual-engine” strategy but also mark its evolution from a primarily license-in model to one integrating robust in-house discovery with global partnerships. With a clinically validated platform, a rich intellectual property portfolio, and a pipeline demonstrating strong potential in cancer and autoimmune diseases, Everest Medicines is well-positioned to redefine its long-term valuation and emerge as a global leader in next-generation mRNA therapeutics.